To assess Ofatumumab Plus Ifosfamide/Etoposide (OIE) combination followed by Autologous Stem Cell Transplantation (ASCT) with carmustine/etoposide/cytarabine/melphalan/rituximab in patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

Trial Profile

To assess Ofatumumab Plus Ifosfamide/Etoposide (OIE) combination followed by Autologous Stem Cell Transplantation (ASCT) with carmustine/etoposide/cytarabine/melphalan/rituximab in patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Carmustine; Cytarabine; Etoposide; Filgrastim; Ifosfamide; Melphalan; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Jan 2017 New trial record
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top